A bill for an act relating to the opioid settlement fund, making appropriations and disbursements, and including effective date and retroactive applicability provisions. (Formerly HSB 331.) Effective date: 06/06/2025, 07/01/2025. Applicability date: 07/01/2024.
House File 1038 creates and governs Iowa’s opioid settlement fund and directs how state opioid settlement dollars are to be deposited, protected, and spent. The bill requires the state portion of national opioid litigation settlement payments to be placed in a separate fund in the state treasurer’s office, keeps those moneys from reverting to the general fund, and limits their use to abating the opioid crisis. It also specifies that interest and earnings remain with the fund or the receiving agency, and it sets a framework for annual reporting, outcome tracking, and administrative rulemaking by the Department of Health and Human Services and the attorney general.
The bill also makes a large fiscal appropriation for fiscal year 2024-2025 from the opioid settlement fund to the Department of Health and Human Services, with targeted disbursements to nonprofit and behavioral health-related entities. These grants support recovery housing, medication-assisted treatment, jail-based screening and treatment, peer recovery services, recovery community centers, recovery cafes, women’s recovery respite, youth recovery programming, and related opioid-use-disorder treatment and prevention efforts. Several appropriations are geographically and organizationally targeted, and the bill requires recipients to comply with settlement requirements, use outcome measures, and report results back to the state.
In terms of state law, the bill amends Iowa Code section 12.51 to expand and clarify the opioid settlement fund structure, the roles of HHS and the attorney general, and the rules for disbursement, oversight, and reporting. It also creates a one-time FY 2024-2025 appropriation of $29 million from the fund and makes the division effective immediately upon enactment, with retroactive applicability to July 1, 2024. The bill therefore affects both the legal administration of settlement proceeds and the distribution of those proceeds to specific opioid-response programs and providers.
The overall sentiment around the bill appears strongly supportive. The recorded floor votes were overwhelmingly favorable, including one unanimous vote and another vote with only one dissenting member, suggesting broad bipartisan agreement on the need to direct opioid settlement dollars toward treatment, recovery, and prevention. The bill’s structure reflects a consensus that settlement funds should be used for opioid-abatement purposes rather than general state spending.
The main points of contention, to the extent they are visible from the bill text, are not about whether the money should be used for opioid response but about how it should be allocated. The bill uses highly specific, named, and geographically targeted appropriations for particular nonprofits and behavioral health districts, which can raise questions about fairness, transparency, and whether funds should be distributed through a more competitive or formula-based process. It also gives HHS and the attorney general discretion to distribute funds equally among administrative services organizations but does not require equal distribution, which may be another point of policy debate.
HF 1038 amends Iowa’s opioid settlement fund statute to formalize the deposit, nonreversion, interest, and spending rules for opioid settlement proceeds and to require state oversight, outcome measurement, and annual reporting. It appropriates $29 million from the fund for FY 2024-2025 and directs those dollars to specific treatment, recovery, housing, and crisis-response programs, primarily through the Department of Health and Human Services and the attorney general. The bill affects the state treasury, HHS, the attorney general, administrative services organizations, nonprofit providers, behavioral health districts, and local opioid-response initiatives.
The bill appears to have enjoyed broad, bipartisan support and little visible opposition. The recorded votes were overwhelmingly in favor, including one unanimous passage and another near-unanimous passage, indicating general agreement with dedicating opioid settlement funds to abatement, treatment, and recovery services. The discussion context provided does not show committee controversy, and the bill’s final posture suggests it was viewed as a practical spending and implementation measure.
The most notable policy tension is over the bill’s highly specific earmarks. Rather than distributing all settlement funds through a broad grant process, the bill names particular types of providers, population-based locations, and service models, which may prompt concerns about favoritism or limited competition. Another potential point of debate is the balance between centralized state oversight and local flexibility: HHS and the attorney general must review proposed uses and track outcomes, but the bill also allows targeted disbursements to specific entities and districts. No explicit opposition is shown in the available transcripts or votes, so any contention appears to be structural rather than partisan.